Home / Market News / $CRL

$CRL news and market catalysts

The 35 most recent market catalysts affecting $CRL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

35 catalysts 5 high impact 27 bullish 2 bearish Biotechnology & Pharmaceutical Services
Nov 12, 2026 Corporate Catalyst Bullish Impact 55
Charles River Laboratories and Toxys Expand Collaboration
Charles River Laboratories announced an expanded collaboration with Toxys, integrating Toxys' ToxTracker and ReproTracker into its service offerings. This partnership allows Charle…
Nov 11, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Adjusts Charles River Laboratories Price Target to $388 From $325, Maintains Buy Rating
TD Cowen, an analyst firm, updated its price target for Charles River Laboratories International, Inc. (CRL) to $388 from $325 and maintained its Buy rating. This indicates a more …
Nov 9, 2026 Corporate Catalyst Bullish Impact 92
Charles River to Acquire Frontage Bioanalysis, DMPK Businesses for $470 Million
Charles River Laboratories is acquiring the bioanalysis and DMPK operations from Frontage Laboratories for $470 million in cash. This move is significant as it directly expands Cha…
Nov 5, 2026 Corporate Catalyst Neutral Impact 65
Financial Institutions Adjust Price Targets for Charles River Laboratories Following Q3 Earnings
This filing indicates that multiple financial institutions have raised their price targets for Charles River Laboratories (CRL) after the company's Q3 2026 earnings report. This ma…
Nov 5, 2026 Corporate Catalyst Bullish Impact 60
Jefferies Adjusts Price Target on Charles River Laboratories International to $385 From $340
Jefferies, an investment firm, has raised its price target for Charles River Laboratories International (CRL) from $340 to $385. This action signifies an improved valuation outlook…
Nov 4, 2026 Corporate Catalyst Neutral Impact 65
Charles River Laboratories Announces Third-Quarter 2026 Results
Charles River Laboratories International, Inc. has filed an 8-K to announce its third-quarter 2026 financial results. This is a standard quarterly disclosure for publicly traded co…
Oct 27, 2026 Corporate Catalyst Neutral Impact 55
Charles River to Use VCG Database in GLP Study for Ipsen
Charles River Laboratories announced a new engagement where its VCG database and methodology will be used by Ipsen for a GLP study. This is significant as it highlights Charles Riv…
Oct 26, 2026 Corporate Catalyst Neutral Impact 55
Charles River Laboratories International Insider Sells Shares
A regulatory filing revealed an insider at Charles River Laboratories International sold $8.4 million in company stock. This matters because insider selling, especially of a signif…
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340
Morgan Stanley analyst Ricky Goldwasser raised the price target for Charles River Laboratories (CRL) from $300 to $340 while maintaining an Overweight rating. This action signals i…
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions
Charles River Laboratories International (CRL) has announced a partnership with Magellan Stem Cells, an Australian biotech firm. This collaboration positions CRL to provide critica…
Oct 6, 2026 Corporate Catalyst Bullish Impact 55
Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration
Charles River Laboratories (CRL) announced the launch of Apollo Orchestrate, a new digital laboratory execution system developed in partnership with Autolomous. This system, built …
Sep 30, 2026 Corporate Catalyst Neutral Impact 55
UBS Reinstates Buy on Charles River, Announces $357 Price Target
UBS analyst Kevin Caliendo reinstated a 'Buy' rating on Charles River (CRL) and announced a $357 price target. This analyst action is a positive signal for the company, suggesting …
Sep 28, 2026 Corporate Catalyst Bullish Impact 55
Jefferies Maintains Buy on Charles River, Raises Price Target to $340
Jefferies analyst David Windley maintained a 'Buy' rating on Charles River (CRL) and raised the price target from $305 to $340. This action signals an analyst's increased convictio…
Sep 25, 2026 Corporate Catalyst Bullish Impact 55
Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320
Deutsche Bank analyst Justin Bowers maintained a 'Buy' rating on Charles River (CRL) and raised the price target from $300 to $320. This action signals a positive outlook from a pr…
Sep 25, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Buy on Charles River, Raises Price Target to $325
TD Cowen analyst Charles Rhyee has maintained a 'Buy' rating on Charles River (CRL) and raised the price target from $300 to $325. This action signals continued confidence in the c…
Sep 25, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330
Evercore ISI Group analyst Ross Muken maintained an 'Outperform' rating on Charles River (CRL) and raised the price target from $320 to $330. This action indicates that a prominent…
Sep 25, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322
RBC Capital's analyst Ryan Halsted maintained an 'Outperform' rating on Charles River (CRL) and raised the price target from $282 to $322. This action signals a strengthened positi…
Sep 25, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Charles River, Raises Price Target to $330
Barclays analyst Luke Sergott maintained an 'Overweight' rating on Charles River Laboratories (CRL) and raised the price target from $300 to $330. This action signals a continued p…
Sep 25, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Neutral on Charles River, Raises Price Target to $295
Mizuho analyst Ann Hynes maintained a 'Neutral' rating on Charles River (CRL) but raised the price target from $264 to $295. This action reflects a slightly improved valuation pers…
Sep 25, 2026 Corporate Catalyst Bullish Impact 55
Baird Maintains Outperform on Charles River, Raises Price Target to $334
Baird analyst Eric Coldwell has raised the price target for Charles River Laboratories (CRL) from $291 to $334 while maintaining an 'Outperform' rating. This action signals increas…
Sep 24, 2026 Corporate Catalyst Bullish Impact 75
Charles River Laboratories International shares are trading higher after the company announced it reiterated its FY26 revenue.
The reiteration of FY26 revenue guidance by Charles River Laboratories International (CRL) is a significant corporate catalyst. In an environment where companies often adjust forec…
Sep 24, 2026 Corporate Catalyst Neutral Impact 75
Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%
Charles River Laboratories International is holding an Investor Day, a common event for companies to update stakeholders on their strategic vision and financial projections. The ke…
Sep 11, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320
Evercore ISI Group analyst Ross Muken maintained an 'Outperform' rating on Charles River (CRL) and raised the price target from $300 to $320. This action signals continued confiden…
Aug 20, 2026 Corporate Catalyst Bullish Impact 55
Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine
Charles River Laboratories and Medigen Vaccine Biologics are partnering to advance Medigen's next-generation multivalent enterovirus vaccine. Charles River will provide its advance…
Aug 10, 2026 Corporate Catalyst Bullish Impact 65
TD Cowen Maintains Buy on Charles River, Raises Price Target to $300
TD Cowen analyst Charles Rhyee maintained a 'Buy' rating on Charles River (CRL) and significantly raised the price target from $235 to $300. This action indicates a strong positive…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $300
Morgan Stanley analyst Ricky Goldwasser has raised the price target for Charles River (CRL) from $260 to $300 while maintaining an 'Overweight' rating. This upgrade signals increas…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $282
RBC Capital analyst Ryan Halsted maintained an 'Outperform' rating on Charles River (CRL) and significantly raised the price target from $215 to $282. This action signals increased…
Aug 6, 2026 Corporate Catalyst Bullish Impact 65
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $300
Evercore ISI Group's analyst Ross Muken maintained an 'Outperform' rating on Charles River (CRL) and raised the price target from $260 to $300. This upgrade signals increased confi…
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
JP Morgan Upgrades Charles River to Overweight, Raises Price Target to $310
JP Morgan's upgrade of Charles River (CRL) from Neutral to Overweight, coupled with a substantial price target increase from $180 to $310, indicates a strong vote of confidence fro…
Aug 5, 2026 Corporate Catalyst Bullish Impact 85
Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High
Charles River Laboratories (CRL) reported Q2 results that beat Wall Street expectations and, more importantly, raised its full-year 2026 financial guidance for both EPS and revenue…
Aug 5, 2026 Corporate Catalyst Bullish Impact 85
Charles River shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates.
This headline is a significant positive catalyst for Charles River Laboratories. Better-than-expected Q2 results indicate strong current performance, while raising FY26 guidance si…
Aug 5, 2026 Corporate Catalyst Bearish Impact 95
Charles River Lowers FY2026 GAAP EPS Guidance from $5.35-$5.85 to $3.05-$3.35 vs $6.24 Est
Charles River (CRL) has announced a significant reduction in its FY2026 GAAP EPS guidance, lowering it from a previous range of $5.35-$5.85 to a new range of $3.05-$3.35. This revi…
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
Charles River Raises FY2026 Adj EPS Guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.12 Est; Raises FY2026 Sales Guidance from $3.794B-$3.854B to $3.879B-$3.920B vs $3.850B Est
Charles River (CRL) announced an upward revision to its fiscal year 2026 adjusted EPS and sales guidance. The new EPS range of $11.15-$11.45 is higher than the previous $10.80-$11.…
Aug 5, 2026 Corporate Catalyst Bearish Impact 92
Charles River Q2 Adj. EPS $3.02 Beats $2.74 Estimate, Sales $1.004B Beat $975.687M Estimate
Charles River (CRL) announced Q2 earnings where both adjusted EPS and sales surpassed analyst expectations. This is a positive short-term signal for the company, suggesting better-…
Jul 13, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Neutral on Charles River, Raises Price Target to $230
Mizuho analyst Ann Hynes maintained a 'Neutral' rating on Charles River Laboratories (CRL) while simultaneously raising the price target from $192 to $230. This action signals that…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.